3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
3
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Hematologic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Interventions
Oxaliplatin
15
Fluorouracil
13
Bevacizumab
13
Leucovorin
10
Capecitabine
8
Folfox protocol
7
Irinotecan
6
IFL protocol
4
Cetuximab
4
Folic Acid
3
Aspirin
3
atezolizumab
2
XELOX
2
Surgical Procedures, Operative
2
Magnetic Resonance Spectroscopy
2
Drug Therapy
2
Chemotherapy, Adjuvant
2
trifluridine tipiracil drug combination
1
trametinib
1
titanium silicide
1
sulindac sulfone
1
spartalizumab
1
sacituzumab govitecan
1
regorafenib
1
raltitrexed
1
pertuzumab
1
irinotecan sucrosofate
1
folfirinox
1
envafolimab
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Colorectal Neoplasms
×
Vemurafenib
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled